TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32200659
Drug: Reference Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Reference Etanercept (50 mg subcutaneous injection)
Study: 33412596
Drug: Heparin (low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (low-molecular-weight heparin or unfractionated heparin)
Study: 43637190
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g oral dose of amoxicillin (Amoxil®)
Study: 43637190
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g oral dose of amoxicillin with 100 mg of sodium diclofenac (Voltaren®)
Study: 35319989
Drug: Combined high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined high-dose radiotherapy and adoptive NK cell transfer
Study: 35183991
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (60 Gy and 45 Gy)
Study: 34162016
Drug: Dinoprostone vaginal
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone vaginal insert (DVI) with adjunctive sweeping of membranes (ASM)
Study: 34047872
Drug: 2% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% CHX gel + AgNP
Study: 36428014
Drug: MEDIC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDIC treatment (patient education, supervised exercise, weight loss, insoles, pain medication)
Study: 34519161
Drug: E‐WAA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: E‐WAA treatment
Study: 33794865
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg) once a day for 3 months
Study: 33794865
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg) and Placebo
Study: 38865168
Drug: Placebo (Ringer's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Ringer's solution)
Study: 33609021
Drug: Propolis extract
Normalized name: PROPOLIS EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis extract gel (2% propolis, 0.2% ascorbic acid, 0.2% tocopherol acetate) applied 3 times/day for a week
Study: 33609021
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied 3 times/day for a week
Study: 34992091
Drug: DCVAC/OvCa parallel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCVAC/OvCa parallel to chemotherapy (Group A)
Study: 34992091
Drug: DCVAC/OvCa sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCVAC/OvCa sequential to chemotherapy (Group B)
Study: 34992091
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (Group C)
Study: 33074442
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell therapy with HSP70 mRNA transfection
Study: 32496624
Drug: Triangular neck
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triangular neck implants
Study: 32496624
Drug: Circular neck
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circular neck implants
Study: 34134822
Drug: Baseline phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline phase (gold-standard exposure therapy training with weekly consultation)
Study: 34531274
Drug: BAY 2253651
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 2253651 (nasally applied genioglossus muscle activator via pharyngeal mucosal receptor stimulation)
Study: 32678677
Drug: Curcumagalactomannosides (CGM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumagalactomannosides (CGM) (400 mg) with glucosamine hydrochloride (GLN) (500 mg)
Study: 32678677
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate (CHN) (415 mg) with glucosamine hydrochloride (GLN) (500 mg)
Study: 32741497
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of drug users in the pretreatment social network
Study: 36165224
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi programme (12 weeks, 45 min per session, twice a week)
Study: 33486385
Drug: Cognitive‐behavioral group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral group therapy (CBGT)
Study: 36000981
Drug: ACT-1014-6470 30
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-1014-6470 30 mg
Study: 36000981
Drug: ACT-1014-6470 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-1014-6470 60 mg
Study: 36000981
Drug: ACT-1014-6470 120
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-1014-6470 120 mg
Study: 35031868
Drug: 1 L-PEG/Asc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L-PEG/Asc
Study: 35031868
Drug: 2 L-PEG/Asc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L-PEG/Asc
Study: 32208229
Drug: Preparation and
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation and planning for discharge
Study: 35459713
Drug: Intra-arterial injection
Normalized name: METHOTREXATE 25 mg in 1 mL INTRA-ARTERIAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-arterial injection of 20 mg lidocaine
Study: 35459713
Drug: Intra-arterial saline
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial saline injection (control)
Study: 32989636
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy-based short-term abstinence intervention (8 sessions of 2.5 hours over 2 weeks)
Study: 34370025
Drug: 10% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% hydrogen peroxide applied once daily for 15 minutes (HP 15)
Study: 34370025
Drug: 10% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% hydrogen peroxide applied once daily for 30 minutes (HP 30)
Study: 35118998
Drug: Non-Dye (ND)
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Dye (ND) group (no contrast injection)
Study: 35118998
Drug: Dye (D)
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dye (D) group (with contrast injection)
Study: 36223555
Drug: Intravesical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical mitomycin (MMC) 40 mg/40 mL three times a week for 2 weeks
Study: 36223555
Drug: TURBT or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: TURBT or office biopsy and 6 weekly adjuvant instillations
Study: 35276223
Drug: Adalimumab Monotherapy
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab Monotherapy (ADL group)
Study: 32018040
Drug: Myo-inositol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol (4 g) and folic acid (400 μg) daily
Study: 32018040
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (400 μg) daily
Study: 36424580
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 μg subcutaneously daily for a mean of 18 months (range 14-24 months)
Study: 34870163
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of intra-articular PRP
Study: 34870163
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of intra-articular PRP
Study: 34870163
Drug: Triple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple dose of intra-articular PRP
Study: 33546944
Drug: Potassium intake
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium intake in 2008–2012: 3147 mg (95% CI 3086–3208) in men; 2784 mg (95% CI 2727–2841) in women.
Study: 33546944
Drug: Adequate potassium
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate potassium intake (≥ 3510 mg/day) prevalence in 2008–2012: 31% (95% CI 28–34%) for men; 18% (95% CI 16–21%) for women.
Study: 35815086
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between control and treatment groups
Study: 34396157
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors and/or beta-blockers
Study: 32236999
Drug: Citalopram associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram associated with Bacopa monnieri (300 mg bid) for 4 weeks
Study: 32236999
Drug: Bacopa monnieri
Normalized name: BACOPA MONNIERI WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacopa monnieri extract (50-200 mg kg-1, p.o.) for 1 week in mouse model
Study: 35084738
Drug: Delgocitinib cream
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Delgocitinib cream 1 mg g‐1
Study: 35084738
Drug: Delgocitinib cream
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Delgocitinib cream 3 mg g‐1
Study: 35084738
Drug: Delgocitinib cream
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Delgocitinib cream 8 mg g‐1
Study: 35084738
Drug: Delgocitinib cream
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Delgocitinib cream 20 mg g‐1
Study: 35084738
Drug: Delgocitinib cream
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Delgocitinib cream (8 and 20 mg g‐1)
Study: 38507100
Drug: Delgocitinib cream
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Delgocitinib cream
Study: 33278671
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg twice daily) plus chemotherapy (gemcitabine and carboplatin)
Study: 33278671
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg twice daily) plus chemotherapy in SqCC with high FDG uptake
Study: 33992285
Drug: Diaphragm Manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm Manual Therapy (DMT)
Study: 32056539
Drug: Saffron extract
Normalized name: saffron extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron extract (affron; 14 mg twice daily)
Study: 34296623
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in treatment preferences (LVAD, unsure, no LVAD)
Study: 34296623
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of treatment preference change
Study: 32006590
Drug: A combination
Normalized name: Enema combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination of atomoxetine and oxybutynin (ato-oxy)
Study: 34110954
Drug: Second- or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second- or third-generation ALK inhibitors after crizotinib therapy
Study: 34023342
Drug: Topical mupirocin
Normalized name: mupirocin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mupirocin (5-day course)
Study: 36037014
Drug: Exercise combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise combined with TCM herbal tea (six substances) taken once daily besides exercise.
Study: 34670012
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 900 mg, twice daily
Study: 35834254
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II Receptor Blockers (ARB)
Study: 35834254
Drug: Angiotensin-Converting Enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-Converting Enzyme Inhibitors (ACEI)
Study: 35834254
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II Receptor Blockers (ARB) in standard systolic blood pressure treatment arm
Study: 35834254
Drug: Angiotensin-Converting Enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-Converting Enzyme Inhibitors (ACEI) in standard systolic blood pressure treatment arm
Study: 35834254
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II Receptor Blockers (ARB) in intensive systolic blood pressure treatment arm
Study: 35834254
Drug: Angiotensin-Converting Enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-Converting Enzyme Inhibitors (ACEI) in intensive systolic blood pressure treatment arm
Study: 32748572
Drug: Retraining and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retraining and Control Therapy (ReACT); 8 sessions
Study: 32748572
Drug: Supportive therapy;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy; 8 sessions
Study: 35671598
Drug: Bilateral QLB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral QLB with Dexmedetomidine 1 μg/kg (Group B)
Study: 32816351
Drug: Biweekly methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Biweekly methotrexate (MTX) 30 mg/m2 + vinblastine (VBL) 6 mg/m2
Study: 33513125
Drug: Conventional hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Conventional hydrocortisone treatment
Study: 33167760
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no stimulant)
Study: 33517894
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care model with nurse care manager (NCM) support for medication treatment of OUD
Study: 33952620
Drug: n-3 (1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 (1,800 mg/day fish oil)
Study: 33952620
Drug: Placebo (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (600 mg/day olive oil)
Study: 35901367
Drug: Summer Treatment
Normalized name: Summers Eve
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Summer Treatment Program-Adolescent (STP-A)
Study: 35363452
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1-g intravenous bolus)
Study: 32349005
Drug: B125S5 (0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: B125S5 (0.125% bupivacaine + 5 μg sufentanil in 15 mL)
Study: 33903052
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy applied to the incision area after abdominal surgery
Study: 34043108
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline with heparin (3000 units to 500 ml of normal saline)
Study: 34043108
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline without heparin
Study: 32592861
Drug: bilateral TBS
Normalized name: TB-402
DrugBank: TB-402 (DB06050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bilateral TBS monotherapy
Study: 33451721
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg/metoclopramide 10 mg
Study: 33199443
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus panitumumab
Study: 33199443
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of anti-EGFR inhibitors to the chemotherapy agent epirubicin
Study: 33262195
Drug: Recombinant tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant tissue-type plasminogen activator (rt-PA) (35-80 mg)
Study: 35319274
Drug: CBD (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (2.5 mg):THC (0.035 mg/kg) ratio (1:1)
Study: 35319274
Drug: CBD (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (2.5 mg):THC (0.035 mg/kg) ratio (2:1)
Study: 35319274
Drug: CBD (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (2.5 mg):THC (0.035 mg/kg) ratio (3:1)
Study: 33440084
Drug: Inhaled treprostinil
Normalized name: treprostinil Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled treprostinil (72 µg, four times daily)
Study: 34193105
Drug: Coping Cat
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping Cat Cognitive Behavioral Therapy (CBT)
Study: 34193105
Drug: Optimization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimization of Stage 1 treatment
Study: 34193105
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (optimization of Stage 1 treatment + addition of the other intervention)
Study: 38740044
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and chemotherapy
Study: 35969402
Drug: Casirivimab and
Normalized name: Casirivimab and Imdevimab
DrugBank: Casirivimab (DB15941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Casirivimab and Imdevimab 1200 mg IV
Study: 35969402
Drug: Casirivimab and
Normalized name: Casirivimab and Imdevimab
DrugBank: Casirivimab (DB15941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Casirivimab and Imdevimab 2400 mg IV
Study: 35969402
Drug: Casirivimab and
Normalized name: Casirivimab and Imdevimab
DrugBank: Casirivimab (DB15941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Casirivimab and Imdevimab 600 mg SC
Study: 35969402
Drug: Casirivimab and
Normalized name: Casirivimab and Imdevimab
DrugBank: Casirivimab (DB15941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Casirivimab and Imdevimab 1200 mg SC
Study: 33844995
Drug: Tremelimumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (1 mg/kg bodyweight) and durvalumab (20 mg/kg bodyweight) every 4 weeks for four doses, followed by maintenance intravenous durvalumab at the same dose and schedule for nine doses.
Study: 33844995
Drug: Retreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retreatment with the same doses and schedules for tremelimumab and durvalumab.
Study: 32873114
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (practiced PMR for two weeks with additional daily placebo treatment)
Study: 32019222
Drug: Probiotic Lactobacillus
Normalized name: Probiotic Lactobacillus Acidophilus Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14, administered orally, twice daily for 12 weeks
Study: 32019222
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered orally, twice daily for 12 weeks
Study: 34648913
Drug: Reduced RUTF
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced RUTF dose (intervention arm)
Study: 34648913
Drug: Standard RUTF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard RUTF dose (control arm)
Study: 33564872
Drug: All supplements
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All supplements (MAGs, EEs, TGs)
Study: 35917580
Drug: R‐Vera 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐Vera 300 mg/day
Study: 35917580
Drug: R‐Vera 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐Vera 450 mg/day
Study: 34217769
Drug: Prenatal steroids
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal steroids (2 or more doses)
Study: 33532885
Drug: Standard administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard administration (day 2)
Study: 33648489
Drug: Self-administered tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered tests for chronic PGP assessment
Study: 33648489
Drug: Self-administered tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered tests
Study: 33648489
Drug: Self-administered tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered tests vs. clinical examination tests
Study: 35485068
Drug: Mexidol 125
Normalized name: Brexidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol 125 mg twice daily
Study: 35485068
Drug: Mexidol 125
Normalized name: Brexidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol 125 mg daily + placebo
Study: 32821038
Drug: Incisional negative-pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional negative-pressure wound therapy (n=785)
Study: 35608027
Drug: Electroacupuncture (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (twice a week for 30 minutes for 8 weeks)
Study: 34593311
Drug: NHFOV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHFOV therapy
Study: 34593311
Drug: NIPPV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIPPV therapy
Study: 33093947
Drug: Acalabrutinib in
Normalized name: Product containing acalabrutinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib in combination with R-CHOP
Study: 33168602
Drug: Tacrolimus (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (0.05 mg/kg twice-daily) plus low-dose corticosteroid (0.5 mg/kg prednisolone once-daily)
Study: 33168602
Drug: High-dose corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroid (1 mg/kg prednisolone once-daily)
Study: 33168602
Drug: Maintenance tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintenance tacrolimus (3-8 ng/ml) plus tapered steroid
Study: 33168602
Drug: Tapered steroid
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapered steroid alone
Study: 36098857
Drug: Cadmium concentrations
Normalized name: cadmium
DrugBank: Cadmium (DB14085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadmium concentrations (0, 10, 25, 50, 75 and 100 mg kg‐1)